Literature DB >> 7873392

Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload.

F N al-Refaie1, L N Sheppard, P Nortey, B Wonke, A V Hoffbrand.   

Abstract

Single oral dose pharmacokinetics of the iron chelator deferiprone (L1) were studied in 24 patients with chronic iron overload and correlated with 24 h urinary iron excretion (UIE) and creatinine clearance. Absorption of L1 was rapid with a t1/2 of 22.2 +/- 17.7 (mean +/- SD) min. The elimination half-life (elt1/2) of the drug was 91.1 +/- 33.1 min and of its metabolite, L1-glucuronide (L1G) 147.7 +/- 52.0 min. Creatinine clearance of the patients correlated significantly with the elimination t1/2 of L1G (r = -0.79, P = 0.002). There was also a significant correlation between 24 h UIE in the 14 patients studied and L1 versus time area under the curve (AUC) (P = 0.007). The total amount of L1 recovered in urine in 24 h comprised 77.9 +/- 13.3% of the L1 dose. L1 efficiency (the 24 h UIE divided by the amount of iron the oral dose of L1 is capable of binding) in the 14 patients was 3.8 +/- 1.9%. These data show for the first time that the urinary elimination of L1G is influenced by the renal function of the patient. Although no significant accumulation of L1 and L1G will occur in most of the patients if L1 is given more than once daily, in some patients with impaired renal function, L1G may accumulate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7873392     DOI: 10.1111/j.1365-2141.1995.tb03318.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

Review 1.  Clinical research: a tale of two studies.

Authors:  David G Nathan
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

2.  Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.

Authors:  Yesim Aydinok; Patricia Evans; Chantal Y Manz; John B Porter
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

3.  Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

Authors:  Patricia Evans; Reem Kayyali; Robert C Hider; John Eccleston; John B Porter
Journal:  Transl Res       Date:  2010-05-27       Impact factor: 7.012

Review 4.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

5.  Population pharmacokinetics of deferiprone in healthy subjects.

Authors:  Francesco Bellanti; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

6.  The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.

Authors:  Majda Hadziahmetovic; Ying Song; Natalie Wolkow; Jared Iacovelli; Steven Grieco; Jennifer Lee; Arkady Lyubarsky; Domenico Pratico; John Connelly; Michael Spino; Z Leah Harris; Joshua L Dunaief
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-16       Impact factor: 4.799

Review 7.  Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

Authors:  J A Barman Balfour; R H Foster
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

8.  Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.

Authors:  Francesco Bellanti; Giovanni C Del Vecchio; Maria C Putti; Aurelio Maggio; Aldo Filosa; Carlo Cosmi; Laura Mangiarini; Michael Spino; John Connelly; Adriana Ceci; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2016-11-06       Impact factor: 4.335

9.  Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.

Authors:  Saumya S Jamuar; Angeline H M Lai
Journal:  Ther Adv Hematol       Date:  2012-10

10.  Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.

Authors:  Shahina Daar; Anil Pathare; Hanspeter Nick; Ulrike Kriemler-Krahn; Abdel Hmissi; Dany Habr; Ali Taher
Journal:  Eur J Haematol       Date:  2008-12-22       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.